INDICATIONS
DOSTINEX Tablets are indicated for the treatment of hyperprolactinemic
disorders, either idiopathic or due to pituitary adenomas.
DOSAGE AND ADMINISTRATION
The recommended dosage of DOSTINEX Tablets for initiation
of therapy is 0.25 mg twice a week. Dosage may be increased
by 0.25 mg twice weekly up to a dosage of 1 mg twice a
week according to the patient's serum prolactin level.
Dosage increases should not occur more rapidly than every
4 weeks, so that the physician can assess the patient's
response to each dosage level. If the patient does not
respond adequately, and no additional benefit is observed
with-higher doses, the lowest dose that achieved maximal
response should be used and other therapeutic approaches
considered.
After a normal serum prolactin level has been maintained
for 6 months, DOSTINEX may be discontinued, with periodic
monitoring of the serum prolactin level to determine whether
or when treatment with DOSTINEX should be reinstituted.
The durability of efficacy beyond 24 months of therapy
with DOSTINEX has not been established.
HOW SUPPLIED
DOSTINEX Tablets are white, scored, capsule-shaped tablets
containing 0.5 mg cabergoline. Each tablet is scored on
one side and has the letter P and the letter U on either
side of the breakline. The other side of the tablet is
engraved with the number 700.
DOSTINEX is available as follows:
| Bottles of 8 tablets |
NDC 0013-7001-12 |
Storage
Store at controlled room temperature 20° to 25°
C (68° to 77° F) [see USP].
Caution: Federal law prohibits dispensing without prescription.
|
|
